← All trials
NCT01943617
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2013
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Peking UniversityCollaborator
- Capital Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Southern Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Fifth Hospital of Shijiazhuang CityCollaborator
- Tsinghua UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Capital Medical UniversityReponsible party - principal investigator
- Yanbian UniversityCollaborator
- Jiao Tong UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.